Review
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 21, 2020; 26(47): 7444-7469
Published online Dec 21, 2020. doi: 10.3748/wjg.v26.i47.7444
Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of in vivo studies
Zaid Al-Dhamin, Ling-Di Liu, Dong-Dong Li, Si-Yu Zhang, Shi-Ming Dong, Yue-Min Nan
Zaid Al-Dhamin, Ling-Di Liu, Dong-Dong Li, Si-Yu Zhang, Shi-Ming Dong, Yue-Min Nan, Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University & Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, Hebei Province, China
Author contributions: Al-Dhamin Z and Nan YM designed the work, performed the extensive literature search, and drafted the manuscript; Al-Dhamin Z and Liu LD analyzed and interpreted the data; Al-Dhamin Z, Zhang SY, and Dong SM provided important intellectual content by generating the figures and tables; Al-Dhamin Z and Li DD reviewed and edited the manuscript; Nan YM revised the work critically and approved the final version to be published.
Supported by Key Research and Development Program of Hebei Province, No. 19277779D; and The Program of Introduce International Intelligence of Hebei Province.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yue-Min Nan, MD, PhD, Director, Doctor, Professor, Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University & Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, No. 139 Ziqiang Road, Shijiazhuang 050051, Hebei Province, China. nanyuemin@163.com
Received: August 21, 2020
Peer-review started: August 21, 2020
First decision: October 18, 2020
Revised: October 31, 2020
Accepted: November 13, 2020
Article in press: November 13, 2020
Published online: December 21, 2020
Core Tip

Core Tip: Bone marrow (BM)- mesenchymal stem cells (MSCs) are a promising therapy for liver fibrosis. However, several aspects, such as efficiency, of this treatment are vague. This review summarizes the recent advances and effectiveness of BM-MSC therapy, its mechanisms, and related factors by focusing on preclinical in vivo experiments. While BM-MSCs appear to be effective in some cases, cotreatment appears to be a better option. Studies on strategies, implementation routes, and cotreatments are helping to strengthen the efficiency. While the potential of this therapy continues to advance, research is still needed to achieve full potential.